Immunome (IMNM) Proxy filing summary

Executive summary

• Achieved significant pipeline progress in 2025, including positive Phase 3 RINGSIDE trial data for varegacestat and advancement of multiple antibody-drug conjugate (ADC) programs and radioligand therapy candidates.

• Share price doubled over 2025, reflecting market recognition of performance; NDA filing for varegacestat planned for Q2 2026.

• 2026 plans include presenting detailed Phase 3 data, initial lymphoma data for IM-1021, and multiple IND submissions.

• Annual Meeting scheduled for June 9, 2026, to be held virtually to enhance stockholder participation.

Voting matters and shareholder proposals

• Four proposals: election of three Class III directors, ratification of Ernst & Young LLP as auditor for 2026, advisory vote on executive compensation, and advisory vote on frequency of say-on-pay votes.

• Board recommends voting for all director nominees, for auditor ratification, for executive compensation, and for annual say-on-pay votes.

• No other matters are expected to be presented at the meeting.

Board of directors and corporate governance

• Board consists of seven members, divided into three classes with staggered three-year terms.

• Recent appointments include Sandra Swain, M.D. (April 2024) and James Boylan (October 2023).

• Board and committees emphasize diversity, independence, and relevant expertise; majority of directors are independent per Nasdaq standards.

• Board leadership combines CEO and Chair roles, with a lead independent director to reinforce independence.

• Three standing committees: Audit, Compensation, and Nominating, each with defined charters and responsibilities.